Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial

Study limitation reported by the research below: “Subgroup analyses by high-risk features (≥2 HRCAs, high-risk GEP, plasma cell leukaemia) were post-hoc and should be interpreted with caution.”